GSK Pulls H1N1 Vaccine Amid Reports Of Reactions

Law360, New York (November 24, 2009, 2:12 PM EST) -- GlaxoSmithKline PLC is advising Canadian officials to stop administering shots from a batch of the company's H1N1 vaccine after health officials received a higher than expected number of reports of severe allergic reactions.

The U.K.-based pharmaceutical company said Tuesday that it was taking the “cautionary action” because the Public Health Agency of Canada had received a higher number of reports of anaphylaxis with a lot of Arepanrix than it had with other lots of the vaccine. The lot in question contained 172,000 doses, GSK said....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.